Popular topics to explore
Wockhardt Pharma is in the spotlight today with two major
WOCKPHARMA Wockhardt Pharma is in the spotlight today with two major developments: strong Q4 FY26 earnings showing a sharp profit surge, and a ₹16 crore customs penalty over an API classification dispute. The stock is trading bullish despi…
WOCKHARDT PHARMA SUPPORT ZONE SETUP DISCUSSION
WOCKPHARMA Wockhardt Pharma is currently consolidating around an important support area, where repeated buying interest is visible. The recent price structure indicates a possible base formation, while momentum remains cautious. A decisive…
Wockhardt Reports Strong Q1 FY27 Results
Key Highlights Wockhardt reported a significant improvement in Q1 FY27, turning profitable from a loss in the year-ago period. Revenue and EBITDA also recorded strong growth, while EBITDA margin more than doubled on a YoY basis. Financial…
Wockhardt Ltd. – Technical Outlook
WOCKPHARMA continues to maintain a positive medium-term trend after its sharp breakout and subsequent consolidation. Following the strong rally towards ₹2,400, the stock has undergone a healthy correction and is now showing signs of base f…
Wockhardt Ltd Zaynich progress
WOCKPHARMA Wockhardt received U.S. FDA approval for ZAYNICH (cefepime and zidebactam), a novel antibiotic aimed at multidrug-resistant infections, after a long development effort. Market coverage says the drug has been viewed as a potentia…
India’s Biotech Sector Eyes $300 Billion Milestone by 2030, Says Minister Dr. Jitendra Singh
India's bioeconomy is on a massive growth trajectory, projected to reach ₹28.50 lakh crore ($300 billion) by 2030 and cementing the nation's position as a premier global biotechnology hub. According to Union Minister Dr. Jitendra Singh, who…
Orchid Pharma Jumps 11% on Russia Licensing Deal
ORCHPHARMA shares surged 11.39% to ₹1,032.15 after signing a licensing agreement with Russia's Pharmasyntez for its novel antibiotic Exblifep. Pharmasyntez gets exclusive rights to register and market Exblifep in Russia while Orchid manufa…
Wockhardt's Next Act
* WOCKPHARMA has transitioned from a generic drug manufacturer to a global innovator after securing US FDA approval for Zaynich, India’s first indigenously discovered and developed novel antibiotic approved in the US.
* Zaynich targets…
WOCKPHARMA Strong Breakout Confirmation: The stock has given a decisive breakout above the ₹1,500 resistance zone, confirming a bullish trend after a prolonged consolidation.
Retest & Trend Continuation: After the breakout, the stock wit…
WOCKPHARMA - New ATH
The breakout above the previous lifetime resistance signals strong buying conviction, with price entering the price discovery phase where historical resistance no longer exists in WOCKPHARMA
While Most Sectors Struggled, What Did Pharma Get Right in 2026?
Pharmaceutical Industry has emerged as one of the standout performers for Indian investors in 2026, delivering strong returns despite heightened market volatility and shifting global macroeconomic conditions. At a time when several sectors…
Morning Market Insights:
Indian Markets staged a smart recovery again from the lower zones in the last trading session again protecting the support zones of 23200 mark. The volatility is expected to continue in the today/s session as well as the trend of the index…
CGPOWER
### Stocks in News
**CGpower** commissioned an extra high-voltage switchgear unit in Nashik, boosting manufacturing capabilities. *(Positive)*
**!AUROPHARMA** received final USFDA approval for Tofacitinib tablets in 5 mg and 10 mg streng…
WOCKPHARMA Wockhardt has given a strong breakout above the ₹1500 resistance zone with sharp bullish momentum and heavy buying interest visible on the chart.
After the breakout, the stock rallied vertically towards ₹2400, and now ₹2150–₹…
WOCKPHARMA
Pharmaceutical major Wockhardt jumped more than 10% on Monday after the company received approval from the US Food and Drug Administration (FDA) for its novel antibiotic, Zaynich, marking a significant achievement in its long-standing resea…
Could This FDA Approval Mark the Beginning of WOCKPHARMA Biggest Global Opportunity Yet?
WOCKPHARMA is back in focus after receiving approval from the U.S. Food and Drug Administration for its novel antibiotic, a significant milestone in the company's efforts to address the growing global challenge of antimicrobial resistance…
WOCKPHARMA
The US Food and Drug Administration (FDA) has approved Wockhardt’s novel antibiotic Zaynich for the treatment of complicated urinary tract infections (cUTIs) in adults caused by designated susceptible microorganisms. Zaynich, a combination…
WOCKPHARMA Wockhardt Ltd – Emerging Pharma Growth Story Driven by Innovation & Specialty Portfolio
WOCKPHARMA Wockhardt is undergoing a significant transformation from a traditional generic pharmaceutical company to an innovation-led healthcare business. The company has strengthened its focus on specialty medicines, biotechnology, and n…
A range breakout and retest happens when price trades between a fixed support and resistance zone for some time, then breaks above the resistance with strong momentum. After the breakout, price often comes back to test the same breakout zon…
WOCKPHARMA Wockhardt Pharma has reported a strong turnaround in FY26
Wockhardt Pharma has reported a strong turnaround in FY26, posting a consolidated net profit of ₹199–317 crore after a loss last year, with Q4 FY26 profits surging to ₹164–167 crore. Shares jumped up to 10% today (May 5, 2026) following the…
